Trastuzumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trastuzumab" in French language version.

refsWebsite

Global rank French rank

2thelancet.com

2,393^rd place

506^th place

2has-sante.fr

9,562^nd place

535^th place

2nejm.org

2,374^th place

298^th place

2aacrjournals.org

8,869^th place

4,895^th place

1qmul.ac.uk

1,735^th place

168^th place

1sciencemag.org

857^th place

208^th place

1ascopubs.org

low place

7,741^st place

1fda.gov

447^th place

1,409^th place

1nih.gov

4^th place

12^th place

1wikipedia.org

low place

1gene.com

low place

1springer.com

274^th place

223^rd place

1onlinejacc.org

low place

2,587^th place

1oup.com

485^th place

416^th place

1sante.fr

8,603^rd place

517^th place

1legifrance.gouv.fr

265^th place

22^nd place

1laskerfoundation.org

low place

aacrjournals.org

Ogitani Y, Aida T, Hagihara K et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1, Clin Cancer Res, 2016;22:5097-5108
Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate, Cancer Res, 2008;68:9280-9290

ascopubs.org

jco.ascopubs.org

(en) Leyland-Jones B, Gelmon K, Ayoub JP et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-3971

fda.gov

Dossier de presse FDA (22 février 2013)

gene.com

(en)Notice pharmacologique (en anglais)

has-sante.fr

[PDF]Synthèse d'avis HAS (9 janvier 2013)
[PDF]Synthèse d'avis HAS (16 février 2011)

laskerfoundation.org

2019 Lasker~DeBakey Clinical Medical Research Award, Herceptin—a targeted antibody therapy for breast cancer sur le site de la fondation Lasker

legifrance.gouv.fr

Avis relatif aux prix de spécialités pharmaceutiques publiés en application des articles L. 162-16-5 et L. 162-16-6 du code de la sécurité sociale (lire en ligne)

nejm.org

content.nejm.org

(en) Hudis CA, Trastuzumab — Mechanism of Action and Use in Clinical Practice, N Eng J Med, 2007;357:39-51
(en)Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 2001;344:783-792

nih.gov

ncbi.nlm.nih.gov

S. Verma et al., « Trastuzumab emtansine for HER2-positive advanced breast cancer », The New England journal of medicine, vol. 367, n^o 19,‎ 2012, p. 1783-1791 (PMID 23020162, lire en ligne, consulté le 27 février 2013) modifier

onlinejacc.org

content.onlinejacc.org

Chen J, Long JB, Hurria A et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer, J Am Coll Cardiol, 2012;60:2504-2512

oup.com

academic.oup.com

Lewinter C, Nielsen TH, Edfors LR et al. A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer, Eur Heart J, 2022;43:2562–2569

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sante.fr

ansm.sante.fr

« Protocole temporaire de traitement Trastuzumab (Herceptin®) en situation adjuvante », sur ansm.sante.fr, 2005

sciencemag.org

(en) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, DJ Slamon, GM Clark, SG Wong, WJ Levin, A Ullrich, WL McGuire, Science, 1987;235;4785;177-182

springer.com

rd.springer.com

Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials, Breast Cancer Res Treat, 2008;109:231–239

thelancet.com

(en) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart, Lancet 2007;369:29-36
(en)Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet, 2010;375:377-384

wikipedia.org

fr.wikipedia.org

S. Verma et al., « Trastuzumab emtansine for HER2-positive advanced breast cancer », The New England journal of medicine, vol. 367, n^o 19,‎ 2012, p. 1783-1791 (PMID 23020162, lire en ligne, consulté le 27 février 2013) modifier